乳腺癌亚型对放疗反应及潜在放疗敏感性的影响

doi:10.11904/j.issn.1002-3070.2016.02.013

摘要/Abstract

摘要： 放射治疗(RT)对于乳腺癌至关重要,有超过50%的患者在治疗疾病的过程中接受RT,相当于全世界每年有500 000名患者接受RT,不幸的是,并不是所有的病人均能获益,部分乳腺癌患者出现了局部复发及远处转移,因此个体化放射治疗将会是一个新局面,对于放疗不敏感的肿瘤给予更高的治疗剂量,而对于放疗无效的疾病避免了不必要的损伤,更具选择性的治疗将节约卫生服务资源,减轻放射治疗机器的负担,降低癌症治疗的经济成本,但目前还没有完善的预测放射治疗的生物标志物,本文将回顾性分析探讨乳腺癌分子亚型是否可以成功预测放射治疗的有效性。

关键词: 放射治疗, 乳腺癌, 分子亚型, 敏感性

Abstract: Radiotherapy(RT)is of importance in the management of breast cancer.Over 50% of patients receive RT at some time during the treatment of their disease,equating to over 500 000 patients worldwide receiving RT each year.Unfortunately,not all the patients derive from benefit and some breast cancers are resistant to treatment,as evidenced by distant metastatic spread and local recurrence.Prediction of individual responses to RT may allow a stratified approach to this treatment permitting those patients with radio-resistant tumours to receive higher doses of RT.Also,for those patients unlikely to respond at all,it would prevent from harmful side effects occurring for no therapeutic gain.More selective targeting would better direct National Health Service resources,ease the burden on heavily used treatment RT machines and reduce the economic cost of cancer treatment.Unfortunately,there are no robust and validated biomarkers for predicting RT outcome.We review the available literatures to determine whether classification of breast cancers according to their molecular subtypes may be used to predict successful response to increase morbidity from RT.

Key words: Radiotherapy, Breast cancer, Molecular subtypes, Radiosensitising

中图分类号:

R737.9

师镘茹综述, 鄂明艳审校. 乳腺癌亚型对放疗反应及潜在放疗敏感性的影响[J]. 实用肿瘤学杂志, 2016, 30(2): 154-157.

SHI Manru, E Mingyan. The influences of breast cancer subtypes on reactivity and radiosensitisvity of radiotherapy[J]. PRACTICAL ONCOLOGY JOURNAL, 2016, 30(2): 154-157.

参考文献

1 Ferlay J,Soerjomataram I,Dikshit R,et al.Cancer incidence and mortality worldwide:Sources,methods and major patterns in GLOBOCAN 2012[J].Int J Cancer,2015,136(5):E359-E386.
2 Perou CM,Sorlie T,Eisen MB,et al.Molecular portraits of human breast tumours[J].Nature,2000,406(6797):747-752.
3 Sorlie T,Perou CM,Tibshirani R,et al.Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications[J].Proc Natl Acad Sci USA,2001,98(19):10869-10874.
4 Cheang MCU,Chia SK,David V,et al.Ki-67 index,HER-2 status,and prognosis of patients with luminal B breast cancer[J].J Natl Cancer Inst,2009,101(10):736-750.
5 Lima JF,Brookes CL,Bayani J,et al.P065 Luminal A vs Luminal B:impact of different St.Galllen Ki-67 and PgR cut points in the TEAM study[J].Breast,2015,24:49.
6 Polley MYC,Leung SCY,McShane LM,et al.An international Ki-67 reproducibility study[J].J Natl Cancer Inst,2013,105(24):1897-1906.
7 Polley MYC,Lung SCY,Gao D,et al.An international study to increase concordance in Ki-67 scoring[J].Mod Pathol,2015,28(6):778-786.
8 Yi M,Huo L,Koenig KB,et al.Which threshold for ER positivity:A retrospective study based on 9639 patients[J].Ann Oncol,2014,25(5):1004-1011.
9 Otto MF,Zhouxin S,Giuseppe V,et al.Patterns of recurrence and outcome according to breast cancer subtypes in lymph node-negative disease:results from international breast cancer study group trials VIII and IX[J].J Clin Oncol,2013,31(25):3083-3090.
10 Matuschek C,Kammers K,Boelke E,et al.OC-0149:Adjuvant radiotherapy of regional lymph nodes in breast cancer-a meta-analysis of randomized trials[J].Radiat Oncol,2014,111(1):1-7.
11 Laura S,Omar Q,Watson MB,et al.Proteomic identification of putative biomarkers of radiotherapy resistance:a possible role for the 26S proteasome?[J].Neoplasia,2009,11(11):1194-1207.
12 Marianne K,Srensen FB,Helle K,et al.Estrogen receptor,progesterone receptor,HER-2,and response to postmastectomy radiotherapy in high-risk breast cancer:the Danish Breast Cancer Cooperative Group[J].J Clin Oncol,2008,26(9):1419-1426.
13 Nguyen PL,Taghian AG,Katz MS,et al.Breast cancer subtype approximated by estrogen receptor,progesterone receptor,and HER-2 is associated with local and distant recurrence after breast-conserving therapy[J].J Clin Oncol,2008,26(14):2373-2378.
14 Wang Y,Yin Q,Yu Q,et al.A retrospective study of breast cancer subtypes:the risk of relapse and the relations with treatments[J].Breast Cancer Res Treat,2011,130(2):489-498.
15 Liu FF,Shi W,Done SJ,et al.Identification of low-risk luminal a breast cancer cohort that may not benefit from breast radiotherapy[J].J Clin Oncol,2015,33(18):2035-2040.
16 谢福源,吴秀萍,卓延红,等.改良根治术后腋窝淋巴结阳性乳腺癌放疗疗效与ER、PR及HER-2相关性分析[J].国际肿瘤学杂志,2014,41(1):66-69.
17 Abdulkarim BS,Julie C,John H,et al.Increased risk of locoregional recurrence for women with T1-2N0 triple-negative breast cancer treated with modified radical mastectomy without adjuvant radiation therapy compared with breast-conserving therapy[J].J Clin Oncol,2011,29(21):2852-2858.
18 Haffty BG,Qifeng Y,Michael R,et al.Locoregional relapse and distant metastasis in conservatively managed triple-negative early stage breast cancer[J].J Clin Oncol,2006,24(36):401-402.
19 Li W,Mason KA,Kian A,et al.MK-4827,a PARP-1/-2 inhibitor,strongly enhances response of human lung and breast cancer xenografts to radiation[J].Invest New Drugs,2012,30(6):2113-20.
20 王淑莲,余子豪,宋永文,等.ER和PR及Her-2对改良根治术后腋窝淋巴结阳性乳腺癌放疗疗效的影响[J].中华放射肿瘤学,2010,19(4):307-310.
21 Koboldt DC,Fulton RS,Mclellan MD,et al.Comprehensive molecular portraits of human breast tumors[J].Nature,2012,490(7418):61-70.
22 郑莉,任加强,陈琦,等.HER-2/neu过表达通过PI3K/Akt通路对乳腺癌细胞MCF7中p53基因表达及细胞生长和放疗敏感性的影响[J].中华肿瘤杂志,2004,26(10):594-597.

[1]	王晓雅,肖斌,廖扬,唐荣芝,孙朝晖,李林海. CXCR家族蛋白在不同乳腺癌亚型中的表达及临床预后分析[J]. 实用肿瘤学杂志, 2019, 33(3): 206-210.
[2]	李烁,张楠楠,李亮亮,龙志平,尹慧慧,赵亚双,王帆. 外周血白细胞PDE4C基因甲基化及环境因素交互作用与乳腺癌发病的关系[J]. 实用肿瘤学杂志, 2019, 33(3): 233-238.
[3]	李嘉琪,栾瑾微,张,玉,李香兰. 763例三阴性乳腺癌临床病理特征及复发、转移影响因素分析[J]. 实用肿瘤学杂志, 2019, 33(3): 244-249.
[4]	李珊,赵春波,乔文波. 术中放疗在胰腺癌中的应用进展[J]. 实用肿瘤学杂志, 2019, 33(3): 280-283.
[5]	陈艳波, 孔德嘉, 张金锋, 马志刚. 乳腺癌患者CYP2D6基因多态性与他莫昔芬代谢相关性研究[J]. 实用肿瘤学杂志, 2019, 33(2): 110-114.
[6]	孙江宏, 郝明珠, 姜丹, 国飞, 李晓梅. 乳腺炎、良性增生及乳腺癌FFDM鉴别诊断思路[J]. 实用肿瘤学杂志, 2019, 33(2): 139-141.
[7]	马志杰, 王帆, 赵亚双. 乳腺癌化疗患者生存质量及影响因素分析[J]. 实用肿瘤学杂志, 2019, 33(2): 149-154.
[8]	马质莹, 尚乃舰, 蔡妙田, 沈阳, 姜智允. 孕激素及雌激素受体阳性乳腺癌HER-2受体与钼靶影像学特征及临床病理学特征的相关性分析[J]. 实用肿瘤学杂志, 2019, 33(1): 47-51.
[9]	张攀, 张迪综述, 戴晓波审校. 复发鼻咽癌再程放射治疗的研究进展[J]. 实用肿瘤学杂志, 2019, 33(1): 92-96.
[10]	何煦, 叶尚勉, 董丹丹, 李科. HLA-G在乳腺癌中的表达及意义[J]. 实用肿瘤学杂志, 2018, 32(5): 410-414.
[11]	林荣杰, 尹航, 周云峰. ON123300对ER阳性人乳腺癌MCF-7细胞的影响及机制研究[J]. 实用肿瘤学杂志, 2018, 32(3): 193-197.
[12]	李林(综述), 李志高(审校). 二甲双胍与不同分子亚型乳腺癌的关系[J]. 实用肿瘤学杂志, 2018, 32(3): 267-270.
[13]	杜夜生, 胡松柳, 徐向英. 非小细胞肺癌寡转移的立体定向放射治疗研究[J]. 实用肿瘤学杂志, 2018, 32(2): 154-158.
[14]	郑伟, 许守平, 庞达. 长链非编码RNA Linc00152在泛癌中表达、预后及功能研究[J]. 实用肿瘤学杂志, 2018, 32(1): 7-13.
[15]	殷玉莲, 张卫红, 周悦, 叶媚娜, 陈红风. ERα基因单核苷酸多态性与乳腺癌应用芳香化酶抑制剂引发骨丢失的相关性研究[J]. 实用肿瘤学杂志, 2018, 32(1): 14-18.